title: MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin.
abstract: OBJECTIVE
  To investigate the molecular mechanisms of miRNA in advanced gastric cancers (AGCs) before and after cytoreductive surgery (CRS) + hyperthermic intraperitoneal chemotherapy (HIPEC).
  
  
  METHODS
  A miRNA microarray containing human mature and precursor miRNA sequences was used to compare expression profiles in serum samples of 5 patients with AGC before and after CRS + HIPEC. The upregulation of miR-218 was confirmed by real-time reverse transcription polymerase chain reaction and its expression was analyzed in SGC7901 gastric cancer cells.
  
  
  RESULTS
  miRNA microarray chip analysis found that the level of miR-218 expression was upregulated more than 8 fold after CRS + HIPEC. Furthermore, miR-218 increased gastric cancer cell chemosensitivity to cisplatin in vitro and inhibited gastric cell tumor growth in nude mice in vivo (0.5 vs 0.78, P < 0.05).
  
  
  CONCLUSIONS
  Our results indicated that targeting miR-218 may provide a strategy for blocking the development of gastric cancer and reverse the multi-drug resistance of gastric cell lines.
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Xiang-Liang
authors.initials: XL
authors.lastname: Zhang
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Hui-Juan
authors.initials: HJ
authors.lastname: Shi
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Ji-Ping
authors.initials: JP
authors.lastname: Wang
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Hong-Sheng
authors.initials: HS
authors.lastname: Tang
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Yin-Bing
authors.initials: YB
authors.lastname: Wu
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Fang
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Shu-Zhong
authors.initials: SZ
authors.lastname: Cui
authors.affiliation: Xiang-Liang Zhang, Hong-Sheng Tang, Yin-Bing Wu, Zhi-Yuan Fang, Shu-Zhong Cui, Department of Abdominal Surgery (Section 2), Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China.
authors.forename: Lian-Tang
authors.initials: LT
authors.lastname: Wang
mesh_terms: D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood / Q000235:genetics*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage*; D065426:Cytoreduction Surgical Procedures; D004305:Dose-Response Relationship, Drug; D005260:Female; D005743:Gastrectomy / Q000379:methods*; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D006979:Hyperthermia, Induced; D020128:Inhibitory Concentration 50; D008297:Male; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D035683:MicroRNAs / Q000097:blood / Q000235:genetics*; D008875:Middle Aged; D020411:Oligonucleotide Array Sequence Analysis; D010477:Perfusion; D060888:Real-Time Polymerase Chain Reaction; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013274:Stomach Neoplasms / Q000097:blood / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D013997:Time Factors; D014162:Transfection; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects; D015854:Up-Regulation; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C547471:MIRN218 microRNA, human; D035683:MicroRNAs; D002945:Cisplatin
keywords: Advanced gastric cancer; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; MicroRNA; Multi-drug resistance; miR-218